Recently, there have been surprising advances in directly targeted drugs for KRAS, especially in KRAS (G12C) inhibitors, such as AMG510 (sotorasib) and MRTX849 (adagrasib), which have obtained encouraging results in clinical trials. Excitingly, AMG510 was the first drug-targeting KRAS (G12...
[4]A study of avutometinib (VS-6766) v. avutometinib (VS-6766) + defactinib in recurrent low-grade serous ovarian cancer with and without a KRAS mutation (RAMP 201). ClinicalTrials.gov. Updated March 12, 2024. Accessed January 2, 2025. clinicaltrials.gov/stud [5]FDA官网. ...
不过Sotorasib和Adagrasib都将重头戏放在了一线治疗KRAS G12C突变的非小细胞肺癌之上,但并没有将先发优势转化为商业化优势的两款药物,也将要面临后面仅仅追赶的多款药物的竞争,竞争者们就包括了罗氏、默沙东、诺华等多家巨头。 罗氏已率先发难,近日clini...
Efficacy and safety of IBI351 in combination with sintilimab ± chemotherapy in advanced non-squamous non-small cell lung cancer subjects with KRAS G12C mutation. ClinicalTrials.gov. Updated August 17, 2022. Accessed January 10, ...
https://www.mdanderson.org/cancerwise/targeting-the-kras-mutation-for-more-effective-cancer-treatment.h00-159458478.html [2]美国国家医学图书馆 https://clinicaltrials.gov/ct2/show/NCT03608631 [3]美国国家医学图书馆 https://clinicaltrials.gov/ct2/show/NCT04429542 ...
Anon. n.d. “First-in-Human Study of JNJ-74699157 in Participants With Tumors Harboring the KRAS G12C Mutation - Full Text View - ClinicalTrials.Gov.” Retrieved March 28, 2022a (https://clinicaltrials.gov/ct2/show/NCT04006301?term=ARS-3248&phase=0&draw=2&rank=1).Anon. n.d. “...
[4]A study of avutometinib (VS-6766) v. avutometinib (VS-6766) + defactinib in recurrent low-grade serous ovarian cancer with and without a KRAS mutation (RAMP 201). ClinicalTrials.gov. Updated March 12, 2024. Accessed January 2, 2025. https://clinicaltrials.gov/study/NCT04625270 ...
参考资料: —— Clinical Trials Search - My Cancer Genome —— KRAS mutation: from undruggable to druggable in cancer - Signal Transduction and Targeted Therapy —— 治疗非小细胞肺癌,安进KRAS抑制剂达到80.6%疾病控制率 ——《Nature》:发现一种可有效抗癌并刺激免疫体统的抑制剂编辑...
clinical data of LAC patients, the expression of PD-L1 in tumours in the TP53/KRAS comutation group was increased, and the proportion of CD8 + T cells in TME was higher, which was consistent with the clinical benefit of TP53, KRAS or TP53/KRAS-mutated cancer patients after treatment ...
Efficacy and safety of IBI351 in combination with sintilimab ± chemotherapy in advanced non-squamous non-small cell lung cancer subjects with KRAS G12C mutation. ClinicalTrials.gov. Updated August 17, 2022. Accessed January 10, 2023.